Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05677100 · ClinicalTrials.gov registry record · NA
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
A NA study of Heart Failure and Heart Failure, Congestive, sponsored by Procyrion.
- Recruiting
- Registry status
- NA
- Development phase
- 320
- Enrollment target
- 20
- Study locations
NCT05677100 is a NA study of Heart Failure and Heart Failure, Congestive that is actively recruiting participants, run by Procyrion. The registered enrollment target is 320 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (84% lower). The trial reports 20 study locations across 6 states.
The verdict
NCT05677100, a NA study of Heart Failure and Heart Failure, Congestive, is actively recruiting participants, sponsored by Procyrion.
- RECRUITING
- Registry status
- NA
- Development phase
- 320 participants
- Enrollment target
- 20
- Study locations
Study Summary
Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejection fraction) will be enrolled and randomized 1:1 to either the Aortix system or standard of care medical management.
Conditions Studied
Interventions
- DEVICE Aortix System
Study Locations (20)
Florida
- Ascension Sacred Heart - Pensacola
- Tallahassee Research Institute - Tallahassee
- University of South Florida - Tampa
- BayCare Medical/St. Joseph's Hospital - Tampa
- AdventHealth Tampa - Tampa
- Cleveland Clinic Florida - Weston
California
- John Muir Health - Concord
- Zuckerberg San Francisco General - San Francisco
- San Francisco Veterans Administration - San Francisco
- University of California San Francisco - San Francisco
Arizona
- Banner--University Medical Center Phoenix - Phoenix
- Mayo Clinic - Arizona - Phoenix
- HonorHealth Medical Center - Scottsdale
Georgia
- Emory University Hospital - Atlanta
- Piedmont Healthcare Inc. - Augusta
- Wellstar Research Institue - Marietta
Illinois
- University of Chicago - Chicago
- Advocate IMMC - Chicago
- Advocate Aurora - Good Samaritan - Downers Grove
Kansas
- Ascension via Christi Kansas - Wichita
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 320 participants |
| Start Date | 2023-08-23 |
| Est. Completion | 2027-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05677100
The ClinicalTrials.gov registry entry for NCT05677100 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 320 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (84% lower). The listed sponsor is Procyrion, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Aortix System is the first listed.
NCT05677100 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT05677100 about?
NCT05677100 is a clinical study titled "Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure". Aortix is a circulatory support device for chronic heart failure patients on medical management who have been hospitalized for acute decompensated heart failure (ADHF) and have persistent congestion despite usual medical therapy. Eligible ADHF patients with diuretic resistance (irrespective of ejec...
What is the current status of trial NCT05677100?
This trial is currently recruiting. It is a NA study. The enrollment target is 320 participants. The study started on 2023-08-23. Estimated completion is 2027-08.
What conditions does trial NCT05677100 study?
This clinical trial studies the following conditions: Heart Failure, Heart Failure, Congestive, Heart Failure, Diastolic, Heart Failure, Systolic, ADHF.
What interventions are being tested in trial NCT05677100?
The interventions under investigation include: Aortix System (DEVICE).
Who is sponsoring clinical trial NCT05677100?
This trial is sponsored by Procyrion, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05677100 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
Optimizing Heart Failure Therapies Among Patients With Limited Access in Denver
RECRUITING · NA
-
Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial
RECRUITING · NA
-
Effect of a Quality Improvement Initiative to Address Social Determinants of Health on Rehospitalization Rates in Patients With Heart Failure
RECRUITING · NA
-
Mind Your Heart-II
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.